SEMA7A and multiple sclerosis: To date, increased systemic or tissue levels of Sema7A have been associated with a spectrum of inflammatory disorders, including multiple sclerosis (Costa et al., 2015), interstitial lung disease (Gan et al., 2011), rheumatoid arthritis (Xie and Wang, 2017), and airway allergy (Esnault et al., 2014).